EDN1 and Alzheimer disease: In the AD model, oral high‐dose prescription (PG‐H) significantly improved skin lesions, reduced TEWL, epidermal thickness, and ear swelling, decreased mast cell infiltration and inflammatory factors (IL‐4/6/31, ET‐1), and enhanced barrier hydration.